Wallace Ryan, Calkins Hugh
Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institute, Baltimore, MD, US.
Arrhythm Electrophysiol Rev. 2021 Apr;10(1):26-32. doi: 10.15420/aer.2020.39.
Arrhythmogenic right ventricular cardiomyopathy (ARVC), also called arrhythmogenic right ventricular dysplasia or arrhythmogenic cardiomyopathy, is a genetic disease characterised by progressive myocyte loss with replacement by fibrofatty tissue. This structural change leads to the prominent features of ARVC of ventricular arrhythmia and increased risk for sudden cardiac death (SCD). Emphasis should be placed on determining and stratifying the patient's risk of ventricular arrhythmia and SCD. ICDs should be used to treat the former and prevent the latter, but ICDs are not benign interventions. ICDs come with their own complications in this overall young population of patients. This article reviews the literature regarding the factors that contribute to the assessment of risk stratification in ARVC patients.
致心律失常性右室心肌病(ARVC),也称为致心律失常性右室发育不良或致心律失常性心肌病,是一种遗传性疾病,其特征是心肌细胞逐渐丧失并被纤维脂肪组织替代。这种结构变化导致了ARVC的突出特征,即室性心律失常和心脏性猝死(SCD)风险增加。应着重确定患者室性心律失常和SCD的风险并进行分层。植入式心律转复除颤器(ICD)应用于治疗前者并预防后者,但ICD并非无害的干预措施。在这类总体较为年轻的患者群体中,ICD会带来其自身的并发症。本文综述了有关有助于评估ARVC患者风险分层的因素的文献。